MICROBIAL CONTROL AND IDENTIFICATION

STRATEGIES

METHODS

APPLICATIONS



Dona Reber and Mary Griffin Editors

Microbial Control and Identification

Strategies Methods Applications

Dona Reber and Mary Griffin Editors

To order this book, please visit: go.pda.org/MCID

PDA Bethesda, MD, USA

DHI Publishing, LLC River Grove, IL, USA

$10 \ 9 \ 8 \ 7 \ 6 \ 5 \ 4 \ 3 \ 2 \ 1$

ISBN: 978-1-942911-27-2 Copyright © 2018 Dona Reber and Mary Griffin All rights reserved.

All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system or transmitted in any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the publisher. Printed in the United States of America.

Where a product trademark, registration mark, or other protected mark is made in the text, ownership of the mark remains with the lawful owner of the mark. No claim, intentional or otherwise, is made by reference to any such marks in the book. Websites cited are current at the time of publication. The authors have made every effort to provide accurate citations. If there are any omissions, please contact the publisher.

While every effort has been made by the publisher and the authors to ensure the accuracy of the information expressed in this book, the organization accepts no responsibility for errors or omissions. The views expressed in this book are those of the authors and may not represent those of either Davis Healthcare International or the PDA, its officers, or directors.



Connecting People, Science and Regulation®



This book is printed on sustainable resource paper approved by the Forest Stewardship Council. The printer, Gasch Printing, is a member of the Green Press Initiative and all paper used is from SFI (Sustainable Forest Initiative) certified mills.

PDA Global Headquarters

Bethesda Towers, Suite 600 4350 East-West Highway Bethesda, MD 20814 United States www.pda.org/bookstore 001-301-986-0293

Davis Healthcare International Publishing, LLC

2636 West Street River Grove IL 60171 United States www.DHIBooks.com

We dedicate this book to Cynthia Sarnoski, Ph.D., our long-time mentor and advisor who offered invaluable encouragement and support throughout the writing and editing of this book.

CONTENTS

Foreword	xiii
Preface	xv
About the Editors	xvii

SECTION I – STRATEGIES

I	REGULATORY AND COMPENDIAL GUIDANCE ON MICROBIAL IDENTIFICATION	3
	Tony Cundell	
	Introduction	3
	Regulatory Guidelines	5
	Compendial Guidelines	7
	Detecting and Identifying Fungal Isolates from	
	Manufacturing Facilities	10
	Human Microbiome	14
	Panel-based Molecular Diganostics	16
	Strain Typing	17
	Whole Genomic Analysis for the Detection	
	and Identification of Microbial Pathogens	18
	Conclusions	18
	References	18
	About the Author	22

V

vi	Microbial Control and Identification	
2	MICROORGANISM IDENTIFICATION AND ITS ROLE IN CONTAMINATION CONTROL	23
	Introduction	23
	Background	23
	Identification Methods	25
	How Does the Organism Identification Aid in Finding	
	a Root Cause for Contamination?	28
	Conclusion	39
	References	39
	About the Author	41
3	MEANINGFUL CONTAMINATION	
	CONTROL TRENDING IN BIOLOGICAL MANUFACTURING	43
	Ren-Yo Forng and leanne Mateffy	15
	Purpose	43
	Trending	45
	Process Monitoring	58
	Conclusion	65
	Case Study	66
	References	68
	About the Authors	70
٨		
-	FROM A LOW BIOBURDEN PERSPECTIVE	73
	Hilary Chan and Lynn Johnson	
	Introduction	73
	Microbial Impact and Significance for Patient Safety	
	and Product Quality	78
	Microbial Impact Assessment Considerations	81
	Microbial Impact Assessment Tools	91
	Lifecycle Management and Quality by Design	106
	Summary	108
	Keterences	109
	About the Authors	115

5 QUALITY RISK MANAGEMENT IN THE CONTEXT OF VIRAL CONTAMINATION I Consortium on Adventitious Agent Contamination in Biomanufacturing (CAACB) Introduction Use of QRM Tools Initiation of Risk Management Process Risk Assessment Risk Control Result of Risk Management Process Risk Review References About the CAACB	17
CONTEXT OF VIRAL CONTAMINATION Consortium on Adventitious Agent Contamination in Biomanufacturing (CAACB) Introduction Use of QRM Tools Initiation of Risk Management Process Risk Assessment Risk Control Result of Risk Management Process Risk Review References About the CAACB	17
Consortium on Adventitious Agent Contamination in Biomanufacturing (CAACB) Introduction Use of QRM Tools Initiation of Risk Management Process Risk Assessment Risk Control Result of Risk Management Process Risk Review References About the CAACB	
Biomanufacturing (CAACB) Introduction Use of QRM Tools Initiation of Risk Management Process Risk Assessment Risk Control Result of Risk Management Process Risk Review References About the CAACB	
Introduction Use of QRM Tools Initiation of Risk Management Process Risk Assessment Risk Control Result of Risk Management Process Risk Review References About the CAACB	
Use of QRM Tools Initiation of Risk Management Process Risk Assessment Risk Control Result of Risk Management Process Risk Review References About the CAACB	117
Initiation of Risk Management Process Risk Assessment Risk Control Result of Risk Management Process Risk Review References About the CAACB	124
Risk Assessment Risk Control Result of Risk Management Process Risk Review References About the CAACB	146
Risk Control Result of Risk Management Process Risk Review References About the CAACB	149
Result of Risk Management Process Risk Review References About the CAACB	153
Risk Review References About the CAACB	156
References About the CAACB	161
About the CAACB	161
	163
6 TRENDING OF MICROBIOLOGICAL	
ISOLATES IN THE BIOPHARMACEUTICAL	
ENVIRONMENT	65
Dona Reber	
Regulations and Guidelines	166
Uses for EM Trending	168
EM Sample Types of Monitoring Trended	172
Trending Frequency	172
Microbial Identification Strategy	174
Steps in Isolate Trending	176
Conclusion	191
References	191
About the Author	194
	07
Tim Sandle	
Introduction	197
Organism Characteristics	199
Origins in Pharmaceutical and Healthcare	200
Potential Risk to Patients	203
FDA Alert and the Testing Debate	204
Testing Scope	212

Tests for BCC	212
Assessment of Test Data	216
Summary	219
References	220
About the Author	228

SECTION 2 – METHODOLOGIES

8	OVERVIEW OF CONVENTIONAL AND	
	EMERGING MICROBIAL IDENTIFICATION	
	METHODS	231
	Frank E. Matos and Jennifer R. Reyes	
	Introduction	231
	Microbial Identification: What Method to Use	232
	Isolation of Microorganisms in Pure Culture	234
	Methods for Characterization and Preliminary Screening	235
	Phenotypic Methods for Microbial Identification	241
	Fatty Acid Analysis Using the Midi Sherlock®	246
	MALDI-TOF	248
	Genotypic Methods for Bacterial Identification	249
	Ribotyping	254
	Identification of Fungi	258
	Molecular Methods for Fungal Identification	265
	Use of Contract Laboratories for Microbial Identification	268
	Conclusion	269
	References	269
	About the Authors	273

QUALIFICATION AND IMPLEMENTATION OF MALDI-TOF TECHNOLOGY FOR USE IN A QUALITY CONTROL LABORATORY Jennifer R. Reyes, Frank E. Matos and Gary Kruppa	275
Mass Spectrometry	276
In-House Evaluation	285
Qualification Activities	287
Improvements	293
Routine Use Activities	295
References	298
About the Authors	301

9

	Contents	ix
10	TESTING FOR MYCOPLASMA	
	IN BIOTHERAPEUTICS	303
	Houman Dehghani and Martina Kopp	
	Introduction	303
	General Biology of Mycoplasma	304
	Regulatory Guidelines Traditional Testing Methods for Mysoplasmas	306
	Emerging Rapid Testing Methods for Detection	307
	of Mycoplasma	309
	Conclusion	315
	References	315
	About the Authors	317
11	VIRUS DETECTION AND TESTING METHODS	319
	Cassandra L. Braxton and Maria M. Bednar	
	Introduction	319
	Key Elements	320
	Adventitious Virus Detection	323
	New Rapid Molecular Methods	328
	Advanced Virus Detection Using NGS	330
	Challenges of NGS in a Biopharmaceutical Setting	346
	NGS Regulatory Guidance	349
		351
	About the Authors	352 360
12	DATA INTEGRITY IN THE LABORATORY	361
	Introduction	362
	What are Data?	363
	Requirements for Data Integrity	363
	Data Pedigree	364
	Regulatory Expectations for Data Integrity	365
	Difficulties in Having Complete Data	366
	Evaluating Data Integrity in the Laboratory	367
	Triggers for Checking Data Integrity in the Laboratory	369
	The Effect of Personnel Behavior on Data Integrity	375
	Conclusion	376
	Keterences	376
	Adout the Author	3//

SECTION 3 – APPLICATIONS

13	DISINFECTANT PERFORMANCE AGAINST	
	FUNGI, VIRUSES AND BACTERIA	381
	James Polarine, Jr., David Shields, and Jennifer Loughman	
	Introduction	381
	Disinfectant and Sporicide Activity against Fungal Spores	382
	Disinfectant and Sporicide Activity against Viruses	391
	Disinfectant and Sporicide Activity against Bacteria	393
	Conclusion	400
	References	40 I
	About the Authors	403

14 ENVIRONMENTAL ISOLATES IN

PHARMACEUTICAL MANUFACTURING	405
Angel L. Salamán-Byron	
Introduction	405
Regulatory and Compendia Guidance	406
Evaluation and Selection of Els	409
Application Els in Pharmaceutical Test Methods	421
Conclusion	426
References	427
About the Author	438

15 MANAGING STOCK CULTURES 439

Vanessa Vasadi-Figueroa	
Introduction	439
Applications and Use	440
Top Six Lineup	441
Culture Libraries	442
Handling	443
Storage Methods	444
Cryopreservation	446
Lyophilization	448
Culture Recovery	449
Market Availabilities	452
Documentation and Inventory Management	454
Conclusion	454
References	455
About the Author	456

	Contents	xi
16	COMPETENCY-BASED TRAINING APPROACH FOR MICROBIAL IDENTIFICATIONS Edward S Balkovic and Gary C du Moulin	457
	Scope of Microbiology Based Training	461
	Expectations for Establishing the Training Program	462
	Expectations for Those Participating in the Training Program	466
	Training Material Development	469
	Training Phase – Process	474
	Training Phase – Task Specific Considerations	478
	Assessment Phase	484
	Summary	486
	References	487
	About the Authors	491
17	MOLD CONTAMINATION IN THE	
17		103
	Brian G Hubka and Jeanne Moldenhauer	7/5
	What is Mold?	493
	Why do I Care About Mold?	494
	Criteria for Mold Growth	499
	Mold Detection and Identification	501
	Setting Limits for Mold Contamination	509
	Mold Remediation Methods	511
	Mold Prevention Methods	514
	References	517
	About the Authors	520
10		
18	FOR THE BIOPHARMACEUTICAL INDUSTRY	523
	Jessica Avizinis	
	Relevance of Biosafety to Drug Development,	
	Manufacturing and Testing Operations	524
	The Importance of Biosafety: Impacts of Exposure	527
	Key Features of a Biosafety Program	530
	Future Biopharmaceutical Biosafety – Special Challenges	560
	Conclusion	561
	References	562
	About the Author	567
Index		569

FOREWORD

Many years have gone by since I first dabbled in microbiology, specifically as it relates to the manufacture of medical products and the impact microbiology has upon the pharmaceutical industry worldwide. I would have greatly appreciated being better versed back in those days with *Strategies*, *Methods*, *Applications*, all topics that remain to be within our focus and scientific realm of interest.

The book's stable of authors are subject matter experts, world renowned and highly respected microbiologists in their respective field of science. That said, you will appreciate reading their depth and breadth of experience regarding current microbiological challenges. For example, Cundell, Moldenhauer, Mateffy and Sandle provide their perspectives on strategies that you will find worthy of your consideration.

The microbiological control and identification as well as microbiological assessment are areas that we all, and quite rightly so, continue to focus our energies and resources. Part and parcel with microbial identification includes trending of the microbial data and corrective measures that may need to be implemented to preclude and/or reduce the presence of microbial and bacterial endotoxin contamination. We all appreciate an inability to escape

xiii

xiv

from having a scientific discussion without including some form of risk assessment and risk management, which is no less important with regards to viral inactivation. I dare say you will find the chapter worthy of your read.

The rapid microbiological methods (e.g., MicroSEQ®, MALDI-TOF) are more common place in todays' laboratories and a far cry from someone who used to prepare a sea of the biochemicals, micro-bial test reagents, poured a river of agar plates and yes, indeed I washed my share of test tubes. The chapter includes laboratory equipment qualification considerations that historically may have not been performed by the laboratory staff. The reader will find it rewarding as they come to better understand and better appreciate how the equipment qualification can impact the microbiological results.

There is a subject that has captured much of our time and to a notable extent has stretched precious resources. Jeanne Moldenhauer provides welcomed guidance and perspectives on this subject, Data Integrity, which you will find worthy of consideration to address and implement the necessary measures to preclude the accidental or unintentional deletion or omission of microbiological data.

I continue to assess how well a company understands the microbiological impacts upon the manufacturing processes. Irrespective of whether the commodity is sterile or non-sterile, a comprehensive microbiological assessment is value added to any manufacturing operation. Equally important, which all have heard me say throughout the years, did the comprehensive assessments include a Microbiologist at the discussion table during the evaluation and implementation process. The individual topics within the text are of welcomed value to any organization. That said, when considering the *Strategy, Methods and Applications, collectively*, I would point out that is not unlike how I might possibly assess a medical products manufacturer.

Thomas J. Arista June 14, 2018

PREFACE

It has been six years since we edited our initial volume on *Microbial Identifications: The Keys to a Successful Program* for the PDA and DHI Publishing, LLC. Microbial identification continues to evolve with new technologies and expectations, yet remains so fundamental to microbial control of quality biopharmaceutical products.

We decided it was the perfect time to once again bring together a group of expert microbiologists and biopharmaceutical industry leaders to discuss microbial identifications in a new light, that of how microbial identification knowledge is a cornerstone in the concept of microbial and contamination control programs. The chapters show how microbial control programs for our facilities, equipment and personnel result in a positive impact on our products and ultimately our patients.

Some of these authors were included in our initial volume and we welcome them back for their continued support and excellent and informative chapters: Drs. Anthony M. Cundell, Jeanne Moldenhauer, Martina Kopp and Houman Dehghani. The remaining authors are new for us, but not to our industry by any means – all are

XV

xvi

well known for their expertise, and we are very pleased that they have joined us here. Please open the book and you will most likely recognize some of these authors, others are newcomers to writing chapters, and we are delighted they all rose to the challenge.

This book has three sections: Strategies, Methods and Applications. Strategies cover regulations and regulatory expectations as well as strategies for trending, risk assessments, and risk management. Methods include current best practice microorganism identification methods, both conventional and emerging rapid methods for bacteria, viruses, mycoplasma and fungi. Applications include microbiology laboratory training for identifications, use of environmental and control microorganisms, disinfectant effectiveness and best practices, and an up and coming chapter subject, biosafety for laboratories, manufacturing facilities and personnel.

It is recognized that each author has taken time from his or her very busy schedules and free time because of a passion for microbiology and microbial control, and with it the desire to share knowledge with others in our industry. This is very much appreciated by us. We also share this passion and dedication as evidenced by our many years of working and presenting on microbiological issues.

This text will provide valuable information for the new microbiologist as well as a reference for well-seasoned professionals. We sincerely hope you enjoy the book.

> Dona Reber and Mary Griffin June 2018

ABOUT THE EDITORS

Dona Reber has more than 25 years of academic and industrial microbiology experience, including developing and implementing contamination control strategies for aseptic/non aseptic manufacturing, microbiology testing/development, and managing/ networking microbiology laboratories. She is Senior Manager of Microbiology and Aseptic Support, Global Quality Operations for Pfizer, responsible for assessing aseptic processing facilities, investigations, troubleshooting, and developing policy documents for microbiology.

Dona holds B.S. and M.S. degrees in related sciences, is (SM) NCRM certified, has been a PDA member for 20+ years, and a longtime chair of the Pharmaceutical Micro Expert Discussion Group. She has numerous publications on microbial identifications systems, environmental monitoring and microbiology risk assessments. She has co-authored three PDA Technical Reports: TR#13, Fundamentals of an Environmental Monitoring Program; TR#67, Exclusion of Objectionable Microorganisms from Non Sterile Pharmaceutical, Medical Devices and Cosmetics; and TR#70,

xvii

xviii Microbial Control and Identification

Fundamentals of Cleaning and Disinfection. She is on a PDA Task Force for Low Bioburden Environmental Monitoring. She has participated in instructing new FDA inspectors, and is an instructor for the PDA on TR#13, Fundamentals of an EM Program. She presented at the most recent PDA Micro Conference on environmental monitoring for low bioburden processes.

Mary Griffin, Principal, MG Quality Microbiology Consulting, LLC, is a subject matter expert in microbiology with more than 35 years of academic (University of Michigan; University of Massachusetts) and global biopharmaceutical experience.

She initiated and directed the Quality Control Microbial Science and Technology department at Pfizer (previously Wyeth, Andover, MA) during a period of significant growth. She adapted her extensive knowledge of microorganisms and classical identification techniques to successfully implement both identification and rapid automated detection systems to keep the facility on the cutting edge of novel technologies.

She continues to support the industry as a consultant through the application of her microbiological identification and rapid technologies expertise for microbial control. She holds a M.S. degree in Microbiology and is certified as a Specialist Microbiologist SM (NRCM). She is an active member of the Parenteral Drug Association (New England Chapter) and is published in the pharmaceutical industry.